IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort - PubMed
4 hours ago
- #Clinical Trial
- #Clear Cell Sarcoma
- #Immunotherapy
- Phase II study of Sunitinib and Nivolumab in Clear Cell Sarcoma (CCS) cohort.
- Primary endpoint: 6-month PFS rate was 50.1%, median PFS was 6.2 months.
- 3 out of 21 patients achieved partial response, 14 had stable disease.
- Median overall survival was 17.0 months.
- Main toxicities: lymphocytopenia, leukopenia, anemia, and neutropenia.
- Higher PD-L1 composite score associated with better PFS (21.2 vs. 4.2 months).
- Nivolumab plus Sunitinib shows promise for CCS management.